TMIST导入试验:DBT与DM在40-44岁及≥75岁女性的筛查表现
本研究纳入TMIST导入试验(A4705)中因入组年龄(40-44岁或≥75岁)不符合后续EA1151标准的271例女性,随机分至数字乳腺断层摄影(DBT)或数字乳腺X线摄影(DM)组。结果显示DBT在两组年龄段的召回率、癌检出率、PPV1及PPV3总体优于DM。研究提示DBT可能弥补DM在极端年龄段筛查中的局限。
要点
- 40-44岁组DM癌检出率为0.0/1000,DBT为14.6/1000,差异明显
- ≥75岁组DBT召回率3.6%显著低于DM的10.1%,减少不必要召回
- DBT组6例筛查检出癌,DM组仅1例,DBT优势在年轻组更突出
核心结论
- 在40-44岁和≥75岁女性中,DBT的筛查表现指标总体优于DM。
- DBT可能弥补DM在纳入评估年龄段中的局限性,改善筛查性能。
研究设计与样本
- 前瞻性试验A4705的非计划亚组分析,纳入4个加拿大中心271例因入组年龄不符合EA1151标准的参与者。
- 随机分组为DM组与DBT组,参考标准为参与者最后筛查轮后1年随访结果。
- 40-44岁组中DM组76例、DBT组105例;≥75岁组中DM组46例、DBT组44例。
- DM组与DBT组分别完成389次和482次筛查检查,每组平均每例3.2轮筛查。
关键影像表现/征象
- 8例癌确诊,其中7例为筛查检出,DM组1例、DBT组6例;DBT组另有1例间期癌。
- 40-44岁组DM召回率13.2%,DBT召回率12.0%;≥75岁组DM召回率10.1%,DBT召回率3.6%。
诊断标准与关键数值
- 40-44岁组:DBT的癌检出率为14.6/1000,DM为0.0/1000。
- 40-44岁组:DBT的PPV1为12.2%,DM为0.0%;DBT的PPV3为83.3%,DM为0.0%。
- ≥75岁组:DBT的癌检出率为7.1/1000,DM为7.2/1000。
- ≥75岁组:DBT的PPV1为20.0%,DM为7.1%;两组PPV3均为50.0%。
临床应用与阅片要点
- 对40-44岁有筛查指征的女性,DBT较DM提升癌检出率并改善穿刺阳性预测值。
- 对≥75岁女性,DBT可大幅降低召回率,有助于减少过度诊断和不必要的随访负担。
- 报告时应关注DBT相对DM在不同年龄段对致密型乳腺和不典型征象的显示优势。
局限性
- 本研究为非计划亚组分析,样本量小,仅271例参与者和8例癌。
- 分组在部分指标上事件数不足,无法计算可靠的比例或进行统计推断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Digital breast tomosynthesis (DBT) has shown improved screening performance compared with digital mammography (DM), although the modality is less well-studied in women 40-44 years old and 75 years and older. OBJECTIVE. The purpose of this study was to compare screening performance between DM and DBT in Tomosynthesis Mammographic Imaging Screening Trial (TMIST) Lead-In trial (A4705) participants who were ineligible for transition to the full TMIST trial (EA1151) due to age at trial entry (40-44 or ≥ 75 years). METHODS. A4705, a prospective trial recruiting women 40 years old and older at four Canadian sites from October 2014 to July 2017, randomized participants to undergo multiple screening rounds by DM or DBT. Final EA1151 eligibility incorporated a narrower age range of 45-74 years. This unplanned analysis included a subset of A4705 participants ineligible for transition to EA1151 due to age at entry (40-44 or ≥ 75 years old). Examination-level screening performance metrics were calculated. The reference standard was determined by 1-year follow-up after participants' last screening round. RESULTS. The study included 271 A4705 participants (mean age, 54 ± 17 [SD] years) who were age-ineligible for EA1151; 181 were 40-44 years old (76 and 105 randomized to DM and DBT, respectively), and 90 were 75 years old or older (46 and 44 randomized to DM and DBT, respectively). Participants in the DM and DBT arms underwent 389 and 482 screening examinations, respectively (mean, 3.2 screening rounds per participant in each arm). Eight cancers were diagnosed (seven screen-detected [one by DM; six by DBT]; one interval cancer in the DBT arm). In participants 40-44 years old, DM, compared with DBT, exhibited a recall rate of 13.2% versus 12.0%, a cancer detection rate (CDR) per 1000 examinations of 0.0 versus 14.6, a PPV1 of 0.0% versus 12.2%, and a PPV3 of 0.0% versus 83.3%, respectively. In participants 75 years old and older, DM, compared with DBT, exhibited a recall rate of 10.1% versus 3.6%, a CDR per 1000 examinations of 7.2 versus 7.1, a PPV1 of 7.1% versus 20.0%, and a PPV3 of 50.0% in both arms. CONCLUSION. Screening performance metrics were overall more favorable for DBT than for DM in women 40-44 years old and 75 years old and older. CLINICAL IMPACT. DBT may mitigate limitations of DM and improve screening performance in the evaluated age groups.
引用
- Seely, Yaffe, Warren, et al. TMIST Lead-In Randomized Trial of Breast Tomosynthesis Versus Digital Mammography: Results in Women Ineligible for the Full TMIST Trial Due to Age (40-44 or ≥ 75 Years Old). AJR Am J Roentgenol. 2026. PMID: 41603806. doi:10.2214/AJR.25.34244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。